Voyager Lifts Off With $45M From Third Rock Ventures
This article was originally published in The Pink Sheet Daily
The venture firm’s latest incubated project is a gene therapy start-up targeting CNS disorders. Voyager hopes to have three programs in the clinic by early 2017, targeting Parkinson’s, ALS and Friedreich’s ataxia.
You may also be interested in...
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.
Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.